Last reviewed · How we verify
prabotulinumtoxinA
At a glance
| Generic name | prabotulinumtoxinA |
|---|---|
| Also known as | Jeuveau, Nuceiva |
| Sponsor | Evolus, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Comparison of Dry Needling and Two Botulinum Toxins for Bruxism (NA)
- Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture (PHASE1)
- Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines
- BoTox Into the Sternocleidomastoid Muscles (SCM) (PHASE4)
- Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area (NA)
- Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention (PHASE2)
- Head-to-Head Comparison of All Botulinum Neurotoxin Type A Products for Glabellar Rhytides (PHASE4)
- Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |